Please use this identifier to cite or link to this item:
|Title: ||Chronic inflammation as a determinant of future aging phenotypes|
|Authors: ||Akbaraly, Tasnime N.|
Ferrie, Jane E.
Batty, G. David
Shipley, Martin J.
|Issue Date: ||2013|
|Publisher: ||© Canadian Medical Association|
|Citation: ||AKBARALY, T.N. ... et al., 2013. Chronic inflammation as a determinant of future aging phenotypes. Canadian Medical Association Journal, 185(16), pp. E763-E770.|
|Abstract: ||Background: The importance of chronic inflammation as a determinant of aging phenotypes may have been underestimated in previous studies that used a single measurement of inflammatory markers. We assessed inflammatory markers twice over a 5-year exposure period to examine the association between chronic inflammation and future aging phenotypes in a large population of men and women.
Methods: We obtained data for 3044 middle aged adults (28.2% women) who were participating in the Whitehall II study and had no history of stroke, myocardial infarction or cancer at our study’s baseline (1997–1999). Interleukin-6 was measured at baseline and 5 years earlier.
Cause-specific mortality, chronic disease and
functioning were ascertained from hospital
data, register linkage and clinical examinations. We used these data to create 4 aging phenotypes at the 10-year follow-up (2007–2009): successful aging (free of major chronic disease and with optimal physical, mental and cognitive functioning), incident fatal or nonfatal cardiovascular disease, death from noncardiovascular causes and normal aging (all other participants).
Results: Of the 3044 participants, 721 (23.7%) met the criteria for successful aging at the 10-year follow-up, 321 (10.6%) had cardiovascular disease events, 147 (4.8%) died from noncardiovascular
causes, and the remaining 1855 (60.9%) were included in the normal aging phenotype. After adjustment for potential confounders, having a high interleukin-6 level (> 2.0 ng/L) twice over the 5-year exposure period nearly halved the odds of successful aging at the 10-year follow-up (odds ratio [OR] 0.53, 95% confidence interval [CI] 0.38–0.74) and increased the risk of future cardiovascular events (OR 1.64, 95% CI
1.15–2.33) and noncardiovascular death (OR
2.43, 95% CI 1.58–3.80).
Interpretation: Chronic inflammation, as ascertained by repeat measurements, was associated with a range of unhealthy aging phenotypes and a decreased likelihood of successful aging. Our results suggest that assessing long term chronic inflammation by repeat measurement of interleukin-6 has the potential to guide clinical practice.|
|Description: ||This paper is in closed access.|
|Sponsor: ||The Whitehall II study is supported by grants from the British Medical Research Council (MRC grant no. K013351), the British Heart Foundation, the British Health and Safety Executive, the British Department of Health, the US National Heart, Lung, and Blood Institute (grant no. R01HL036310), the US National Institute on Aging (grant nos. R01AG013196 and R01AG034454) and the US Agency for Health Care Policy and Research (grant no. HS06516).|
|Publisher Link: ||http://dx.doi.org/10.1503/cmaj.122072|
|Appears in Collections:||Closed Access (Sport, Exercise and Health Sciences)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.